Compared to the control group and the TMZ monotherapy group, the weight loss was notably less severe (Fig 8h), and the overall survival time was significantly longer in the group with TSPAN13 knockdown combined with TMZ treatment (Fig 8i), further supporting the role of TSPAN13 in modulating TMZ sensitivity in GBM cells. Here, TSPAN13 is linked to glioblastoma.